You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)與禮來製藥開發之治療肺癌藥品達預設主要研究終點
阿思達克 01-13 12:16

信達生物(01801.HK)公布,集團與禮來製藥共同開發的創新PD-1抑制劑達伯舒(信迪利單抗注射液)的一項在中國的3期臨床研究(ORIENT-11)-達伯舒(信迪利單抗注射液)聯合力比泰(注射用培美曲塞二鈉)和鉑類用於一線治療無EGFR敏感突變或ALK基因重排的晚期或復發性非鱗狀非小細胞肺癌(nsqNSCLC)期中分析達到預設的主要研究終點。

相關研究結果將在近期的學術會議上予以公佈。根據獨立資料委員會(IDMC)建議,信達將在近期與禮來啟動就向國家藥品監督管理局遞交註冊申請的討論。

ORIENT-11研究是一項評估達伯舒(信迪利單抗注射液)或安慰劑聯合力比泰(注射用培美曲塞二鈉)和鉑類用於一線治療無EGFR敏感突變或ALK基因重排的晚期或復發性非鱗狀非小細胞肺癌(nsqNSCLC)有效性和安全性的隨機、雙盲、3期臨床研究(ClinicalTrials.gov,NCT03607539)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account